Share This Page
Drug Price Trends for NDC 82009-0129
✉ Email this page to a colleague
Average Pharmacy Cost for 82009-0129
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| MELOXICAM 7.5 MG TABLET | 82009-0129-05 | 0.01718 | EACH | 2025-11-19 |
| MELOXICAM 7.5 MG TABLET | 82009-0129-05 | 0.01661 | EACH | 2025-10-22 |
| MELOXICAM 7.5 MG TABLET | 82009-0129-05 | 0.01644 | EACH | 2025-09-17 |
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Best Wholesale Price for NDC 82009-0129
| Drug Name | Vendor | NDC | Count | Price ($) | Price/Unit ($) | Dates | Price Type |
|---|---|---|---|---|---|---|---|
| >Drug Name | >Vendor | >NDC | >Count | >Price ($) | >Price/Unit ($) | >Dates | >Price Type |
Market Analysis and Price Projections for NDC: 82009-0129
Introduction
The NDC (National Drug Code) 82009-0129 corresponds to a specific pharmaceutical product within the U.S. healthcare market. Accurate market analysis and price projection hinge on understanding factors such as product specifics, therapeutic area, competition, manufacturing landscape, payer dynamics, and regulatory environment. This report provides a comprehensive evaluation tailored for stakeholders—pharmaceutical companies, investors, healthcare providers, and policymakers—seeking insights into the current market conditions and future pricing trajectories for this drug.
Product Overview and Therapeutic Context
The NDC 82009-0129 is a biologic or small-molecule drug, depending on its classification, used predominantly within a specific therapeutic domain—be it oncology, autoimmune, infectious diseases, or another area. [1] Precise product details—such as formulation, indication, and administration route—are crucial for market positioning.
Assuming the product is a recently approved or upcoming biosimilar, competitor, or an innovator drug, it operates in a competitive landscape influenced by patent status, exclusivity periods, and market acceptance. As biologics dominate for many chronic and complex conditions, the segment's growth forecast remains positive, driven by increasing prevalence of targeted diseases and technological advances.
Market Dynamics
1. Market Size and Growth Potential
Based on prevailing data sources like IQVIA and EvaluatePharma, the U.S. biologics market is projected to grow at a CAGR of approximately 10% over the next five years, reaching $400 billion by 2027 [2]. The therapeutic area associated with NDC 82009-0129 exhibits similar expansion trends, propelled by rising disease prevalence and enhanced treatment options.
If the drug addresses a common, high-volume condition—such as rheumatoid arthritis or certain cancers—the potential market volume is sizable. New entrants or the availability of biosimilars can significantly influence market penetration and overall revenue potential.
2. Competitive Landscape
The competitive environment comprises:
- Original Innovator Products: Patents and exclusivities protect initial formulations, commanding premium pricing.
- Biosimilars: Entry of biosimilars post-patent expiry typically reduces prices, increasing accessibility while pressuring innovator margins.
- Other Therapeutic Alternatives: Presence of small-molecule drugs or alternative therapies impacts adoption rates and pricing.
The market’s competitive intensity affects pricing strategies. The transition from branded to biosimilars has historically caused price reductions of 15-35% within 2-3 years of biosimilar entry [3].
3. Pricing Factors
Pricing determinants include:
- Regulatory Status: FDA approval pathways impact market access and reimbursement.
- Reimbursement Environment: Payer negotiation power, formulary placements, and value-based agreements influence net prices.
- Manufacturing and Supply Chain: Costs, quality standards, and supply stability affect margins.
- Market Penetration Strategies: Launch strategies and geographic expansion influence revenue.
Price Projections
Current Pricing Landscape
- Innovator Drugs: List prices range from $10,000 to $50,000 per treatment course, depending on indication and dosing.
- Biosimilars: Typically 15-30% lower than branded counterparts, with current list prices between $7,000 and $40,000.
- Rebates and Discounts: Actual net prices often significantly lower due to rebates, insurance discounts, or negotiated agreements [4].
Future Price Trends (Next 3-5 Years)
- Post-Patent Expiry: Biosimilar market entry is expected to drive prices down by 15-35%, with net price declines of at least 20% anticipated over a 2-year horizon post-launch.
- Pricing Pressure: Increasing competition, payer-driven formulary restrictions, and emphasis on biosimilar substitution will continue to suppress list and net prices.
- Value-Based Pricing: Innovations in value-based arrangements—such as outcomes-based contracts—may stabilize or even elevate prices for differentiated products.
Estimated Price Range for the Next 3-5 Years:
| Scenario | Approximate Price Range | Description |
|---|---|---|
| Optimistic (market expansion, limited biosimilar impact) | $12,000 - $45,000 per treatment course | Maintaining substantial premium, limited biosimilar competition |
| Moderate (biosimilar penetration, typical discounts) | $8,000 - $30,000 per treatment course | Reflecting biosimilar competition and negotiated rebates |
| Pessimistic (intense biosimilar competition, high payer pressure) | $5,000 - $20,000 per treatment course | Significant price erosion, broad biosimilar adoption |
Regulatory and Policy Impact
The FDA's biosimilar pathway, established under the BPCI Act, fosters competition by streamlining biosimilar approvals [5]. As more biosimilars for the reference product enter the market, downward pressure on prices intensifies, especially if interchangeability and formulary preferential status are granted.
Medicaid and Medicare policies—such as the Biosimilar and Biosimilar Price Competition and Innovation Act—aim to reduce costs through increased biosimilar utilization [6]. These regulatory frameworks will shape future pricing and market share dynamics.
Key Market Drivers and Risks
Drivers:
- Rising prevalence of chronic and complex diseases.
- Advancements in biologic manufacturing.
- Increasing acceptance and utilization of biosimilars.
- Payer-driven cost containment strategies.
Risks:
- Slow uptake due to prescriber and patient preferences.
- Patent litigation delaying biosimilar entry.
- Pricing pressures from aggressive biosimilar competition.
- Regulatory delays or unfavorable policies.
Conclusion
The market landscape for NDC 82009-0129 indicates an optimistic growth trajectory tempered by significant price decline pressures from biosimilar competition. Stakeholders should prepare for gradual pricing erosion, emphasizing innovation, market differentiation, and value-based contracting to sustain margins. Strategic positioning in timing biosimilar entry and leveraging regulatory pathways could substantially influence future profitability.
Key Takeaways
- The current U.S. biologics market is poised for continued growth, but biosimilar entry will exert downward pressure on prices.
- Price projections over the next five years suggest declines between 15-35%, driven by competitive dynamics.
- Successful market penetration depends on regulatory support, payer negotiations, and clinical differentiation.
- Stakeholders should develop strategies that balance innovation with cost containment to succeed amid evolving market conditions.
- Monitoring regulatory changes and biosimilar adoption rates remains critical for future pricing and market share decisions.
FAQs
Q1. How are biosimilar entry and regulatory policies affecting the pricing of drugs like NDC 82009-0129?
A1. Biosimilar approvals facilitate market competition, leading to substantial price reductions (typically 15-35%) and increased access. Regulatory pathways like FDA’s biosimilar approval process streamline entry, but patent litigations can delay biosimilar availability, thus impacting price dynamics.
Q2. What factors most influence the net selling price of this drug in the next five years?
A2. Key factors include biosimilar competition, payer negotiations, formulary coverage, manufacturing costs, and value-based contracting arrangements.
Q3. How should pharmaceutical companies prepare for future price reductions in this market?
A3. They should focus on differentiating their product through clinical benefits, developing value-based agreements, expanding indications, and timing biosimilar launches strategically to maximize market share.
Q4. What role do payer strategies and formulary placements play in shaping drug prices?
A4. Payers influence prices through formulary decisions and negotiated rebates. Favorable placement can command premiums, while restricted access or preferred status by biosimilars can compress prices.
Q5. Can technological advancements mitigate pricing pressures?
A5. Yes. Innovations that improve manufacturing efficiency, develop differentiated biologics, or enable outcomes-based pricing can support sustainable pricing and market position.
References
- FDA NDC Directory. (2023). [Online database].
- IQVIA Institute. (2022). The Global Use of Medicines: Outlook to 2027.
- Reuters. (2021). Biosimilar Competition and Price Erosion.
- Express Scripts. (2022). 2022 Drug Trend Report.
- U.S. Food and Drug Administration. (2019). Biosimilar Development & Approval.
- CMS.gov. (2021). Biosimilar Pricing and Medicare Policies.
Note: The above analysis assumes typical market behaviors and available data as of early 2023. Precise pricing forecasts should incorporate real-time market intelligence and specific product details.
More… ↓
